Monthly Communication Report

Organization:	Psychedelics Canada—The Canada Psychedelic Businesses Association
Associated registration:	952635-372370-1
Communication date:	2022-10-04
Posted date:	2022-11-15

Designated Public Office Holders who participated in the communication:	Jenny-Lee Choon, Acting Manager Office of Controlled Substances, Health Canada (HC) Kathy Soltys, Director Office of Clinical Trials, Health Canada (HC) Jaigi Mathai, Senior Evaluator Office of Clinical Trials, Health Canada (HC) Jennifer Pelley, Director Office of Legislative and Regulatory Affairs, Health Canada (HC) Graeme Simpson, Senior Policy Analyst Office of Controlled Substances, Health Canada (HC) Kristen Beausoleil, Manager Office of Legislative and Regulatory Affairs, Health Canada (HC) Sarah Schlegelmilch, Senior Policy Analyst Office of Legislative and Regulatory Affairs, Health Canada (HC) Marc-André Roy, Associate Director Office of Controlled Substances, Health Canada (HC) Cesare  Spadaccini, Manager Office of Controlled Substances, Health Canada (HC) Daniel Keene, Associate Director Office of Clinical Trials, Health Canada (HC) Jennifer Saxe, Director General Controlled Substances Directorate, Controlled Substances and Cannabis Branch, Health Canada (HC)
Subject Matter of the communication:	Health,  Justice and Law Enforcement,  Science and Technology
Responsible Officer who filed this communication report:	Liam Bedard
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.